Drugs / Ad-P53
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02842125 | Nov 2018 → May 2020 | head and neck squamous cell carcinoma, metastatic malignant neoplasm | MultiVir, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03544723 | Oct 2018 → Jun 2022 | cancer, lymphoma | MultiVir, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-P53 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02842125 ↗ |
| Route | Other | “Ad-p53 administered intra-arterially” NCT02842125 ↗ |